Company news
Kexing Biopharm Co., Ltd. Class A (SSE:688136) news
Every Kexing Biopharm Co., Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in China
October 4, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for GB20 Injection
September 21, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 7, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 21, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Change of Sponsor Representative for Continuous Supervision
August 7, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Vesting Results for the 2nd Vesting Period under the 2024 Restricted Stock Incentive Plan and the Listing of Shares
July 7, 2026
"SHAN DONG KEXING BIOPRODUCTS CO., LTD." Announcement on Granting of Restricted Stocks to Incentive Objects
July 2, 2026
Announcement on the Resignation of Core Technical Personnel
June 26, 2026
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
June 22, 2026
Announcement on the Achievements of Vesting Conditions in the 2nd Vesting Period of the 2024 Restricted Stock Incentive Plan
June 15, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 7, 2026
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection
May 13, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 28, 2026
2025 Annual Report
April 21, 2026
Announcement on Voluntary Disclosure of GB19 Injection Obtaining FDA Clinical Trial Approval for New Drugs
March 30, 2026
Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
March 20, 2026
Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
March 3, 2026
Announcement on Signing Daily Related Party Transaction Agreements
March 2, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GB19 Injection
February 25, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
February 3, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Estimated Amount of Daily Related Transactions in 2026
December 31, 2025
Announcement on Renewing Engagement of Accounting Firm
December 15, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Ophthalmic Preparation GB10 Injection
December 8, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple
November 20, 2025
Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
November 17, 2025
Shareholders' Inquiry Transfer Plan
November 14, 2025
Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products
November 12, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 10, 2025
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
October 31, 2025
Report for Q3 2025
October 29, 2025
BioDlink Completes First International Shipment of Bevacizumab to Colombia
October 27, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 17, 2025
Announcement on Adjusting the Remuneration of Independent Directors
September 30, 2025
Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Registration Application for GB10 Injection
September 29, 2025
Announcement on Voluntary Disclosure of Inclusion of Human Interferon α1b Inhalation Solution Being Included in the List of Drugs Granted Breakthrough Therapy Designation
September 23, 2025
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
September 15, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for Injection
September 2, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 29, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 22, 2025
Announcement on Signing a Supplementary Agreement to Agreement of Related Party Transactions
August 15, 2025
BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
August 13, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
August 11, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 1% Integer Multiple
August 5, 2025
Announcement on General Election of Board of Directors
July 28, 2025
Announcement on Vesting Results and Share Listing in the 1st Vesting Period of the 2024 Restricted Stock Incentive Plan
July 10, 2025
Announcement on Shareholding Changes Reaching 1% Threshold, Completion of Shareholding Reduction Plan and Results of Shares Sold
July 9, 2025